COMPASS Pathways plc (CMPS) stock: key figures, P/E, revenue and dividend
Health Care · United Kingdom · ISIN US20451W1018
COMPASS Pathways plc financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -179.04 m USD |
| EBIT | -293.00 m USD |
| Net income | -287.86 m USD |
| Diluted EPS – continuing operations | -3.08 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About COMPASS Pathways plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
More stocks
- NanJi ECommerce Co Ltd (002127.SZ)
- Bio-Thera Solutions Ltd (688177.SS)
- XPEL, Inc. (XPEL)
- 74Software SA (74SW.PA)
- Sino Geophysical (300191.SZ)
- ANHUI HONGYU WUZHOU Medical Manufacturer Co.LTD. (301234.SZ)
- RLH Properties S.A.B. de C.V (RLHA.MX)
- ShenZhen Kondarl Group Co Ltd (000048.SZ)
- Shanghai Ziyan Foods Co Ltd (603057.SS)
- Accel Entertainment, Inc. (ACEL)
- Hbm Holdings Ltd (2142.HK)
- Pacific Horizon Investment Trust PLC (PHI.L)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.